Meta-analysis of MTHFR 677CT polymorphism and coronary heart disease:
http://www.100md.com
《英国医生杂志》
1 Department of Social Medicine, University of Bristol, Bristol BS8 2PR
Correspondence to: S J Lewis s.j.lewis@bristol.ac.uk
Objectives To investigate the association between the MTHFR 677CT polymorphism and coronary heart disease, assessing small study bias and heterogeneity between studies.
Data sources Medline and Embase citation searches between January 2001 and August 2004; no language restrictions.
Study selection Case-control and prospective studies of association between MTHFR 677CT variant and myocardial infarction, coronary artery occlusion, or both; 80 studies were included.
Data extraction Data on genotype frequency and mean homocysteine concentrations by genotype were extracted. Odds ratios were calculated for TT genotype versus CC genotype. Heterogeneity was explored, with stratification by geographical region of the study samples, and meta-regression by difference in mean serum homocysteine concentrations (CC minus TT genotypes) was carried out.
Results 26 000 cases and 31 183 controls were included. An overall random effects odds ratio of 1.14 (95% confidence intervals 1.05 to 1.24) was found for TT versus CC genotype. There was strong evidence of heterogeneity (P < 0.001, I2 = 38.4%), which largely disappeared after stratification by geographical region. Odds ratios in Europe, Australia, and North America attenuated towards the null, unlike those in the Middle East and Asia.
Conclusions No strong evidence exists to support an association of the MTHFR 677 CT polymorphism and coronary heart disease in Europe, North America, or Australia. Geographical variability may be due to higher folate intake in North America and Europe or to publication bias. The conclusion drawn from previous meta-analyses that folic acid, through lowering homocysteine, has a role in prevention of cardiovascular disease is in some doubt.
Observational studies have consistently shown that higher plasma homocysteine concentrations are associated with an greater risk of coronary heart disease.1 However homocysteinecoronary heart disease associations may be confounded (for example, by smoking and socioeconomic position) and existing atherosclerosis could itself increase homocysteine concentrations.2 3 This last explanation (reverse causality) is supported by evidence that the homocysteine-coronary heart disease associations derived from cohort studies are weaker than those from case-control studies, which are, inevitably, more prone to being biased by existing disease leading to higher homocysteine concentrations.4
Associations between the genetic variant MTHFR 677CT and coronary heart disease have been reported.5 The genetic variant is associated with elevated homocysteine concentrations but, following the principles of mendelian randomisation,6 is not subject to reverse causation or the confounding that exists in observational studies of coronary heart disease risk in relation to directly measured homocysteine concentrations. Indeed, inclusion of folate—which lowers homocysteine concentrations7—in the proposed Polypill (a combination of low dose aspirin, a statin, three blood pressure lowering drugs, and folic acid, intended for prevention of coronary heart disease) is supported by reference to two meta-analyses of such genetic studies, and the evidence of causation is said to be "compelling."8 However, the sample sizes needed for studies to accurately estimate the causal influence of intermediate phenotypes such as homocysteine concentration on disease outcomes by using common genetic variants are necessarily very large,9 and publication bias (selective publication of positive findings) is likely to be a major concern with genetic association studies.10
In their meta-analysis, Wald et al tested for small study bias, reporting an Egger test of P = 0.55.5 Another meta-analysis of the association between MTHFR 677CT and coronary heart disease showed potential publication bias, in which non-publication of small negative studies would lead to overestimation of the strength of association between the MTHFR 677CT variant and coronary heart disease.11 Since the publication of these two meta-analyses several new studies have appeared, including one larger than any previous study.12 Adding these and studies already published but presumably missed by the search strategy used by previous investigators more than doubles the number of cases available for analysis compared with the two previous comprehensive meta-analyses.5 11 We have therefore carried out an updated meta-analysis using a comprehensive literature search and fully investigated potential publication bias. This work is important, as it is essential to define carefully the evidence for inclusion of folic acid in the Polypill, which has been strongly promoted, has been patented, and is in the process of being manufactured.
Methods
We identified eligible studies by searching Medline and Embase for all publications between January 2001 and August 2004, updating the search used in earlier meta-analyses.5 We used the search terms "mthfr," "methylenetetrahydrofolate reductase," "5,10 methylenetetrahydrofolate reductase," "677C," and "C677T" in combination with "cardiovascular disease," "ischemic heart disease," "coronary," "heart disease," "myocardial infarction," and "angina." We did not exclude any studies on the basis of language. We used the outcome as defined by previous investigators of myocardial infarction or coronary artery occlusion (> 50% of the luminal diameter).
We based unadjusted odds ratios on published genotype frequencies or extracted them directly from publications where raw data were not available. We used random effects models.
Where possible, we assessed whether the frequencies of CC, CT, and TT genotypes among controls in individual studies were consistent with the expected distribution (that is, in Hardy-Weinberg equilibrium) by using the Pearson 2 test. In line with previous work, we compared the TT genotype with the CC genotype. In our meta-analysis of all studies, we stratified by the geographical region in which the studies were done—Asia, Australia, the Middle East, North America, and Europe—and gave odds ratios by region. We quantified the extent of heterogeneity by using I2, which represents the percentage of total variation across studies that is attributable to heterogeneity rather than chance.13 Where mean serum homocysteine concentrations were given by genotype, we extracted these for all samples or for controls only where values for all samples were not provided or could not be calculated. We estimated the difference in serum homocysteine concentrations between CC and TT genotypes by using a random effects meta-analysis. We used meta-regression analysis to assess whether differences in serum homocysteine concentration affected MTHFR-disease associations. We used Stata version 8 for all statistical analyses.
We calculated the predicted odds ratio for coronary heart disease risk for a 5 μmol/l increase and a 3 μmol/l decrease in homocysteine concentrations, for comparison with the Wald et al meta-analysis,5 by raising the odds ratio and confidence intervals to the power of 5/2.24 (the overall difference in mean homocysteine between CC and TT genotypes) and to the power of -3/2.24.
Results
In all, we included 81 data points from 80 studies in this meta-analysis (table 1; fig 1), with a total of 26 000 cases and 31 813 controls. We identified 24 studies that we believe fitted the earlier reviews' inclusion criteria,5 11 but which were not included in either of the original meta-analyses either because they were not identified by the original search strategies or because they have been published since this meta-analysis. We found an overall random effect odds ratio for coronary artery disease comparing TT with CC genotypes of 1.14 (95% confidence interval 1.05 to 1.24). Five studies showed evidence to suggest (P < 0.05) that genotypes were not in Hardy-Weinberg equilibrium in controls. However, exclusion of these studies made very little difference to the overall result (odds ratio 1.15, 1.06 to 1.26). We also found evidence that effect estimates were related to study size, suggesting that small study bias, such as publication bias, may have distorted the findings (Egger test P = 0.03).
Table 1 Summary findings by geographical region: odds ratios for coronary heart disease comparing TT with CC genotypes, and difference in geometric mean serum homocysteine concentrations
Fig 1 Results of search strategy
We found strong evidence of between study heterogeneity (P < 0.001, I2 = 38.4%). Stratified analysis by geographical region removed much of the heterogeneity within Europe, North America, Australia, and the Middle East; the random effect odds ratio were 1.08 (0.99 to 1.18; Pheterogeneity = 0.19, I2 = 16.1%) among the 42 European studies, 0.93 (0.80 to 1.10; Pheterogeneity = 0.64, I2 = 0%) among the 15 North American studies, 1.04 (0.73 to1.49; Pheterogeneity = 0.97, I2 = 0%) among the three Australian studies, and 2.61 (1.81 to 3.75; Pheterogeneity = 0.57, I2 = 0%) among the five Middle Eastern studies (fig 2). Evidence of heterogeneity remained between Asian studies, but this was only apparent between Japanese studies and others and within studies done in Japan. The random effects odds ratio for Japanese studies was 1.71 (1.23 to 2.37; Pheterogeneity = 0.01, I2 = 62.5%); studies done in China, Taiwan, and Korea produced homogeneous results, with an overall odds ratio of 0.81 (0.60 to 1.10; Pheterogeneity = 0.41, I2 = 3.0%).
Fig 2 Association between MTHFR C677T polymorphism and coronary heart disease (TT versus CC genotype). *Unpublished data taken from Klerk et al, 2002 meta-analysis
To minimise the effect of inter-laboratory variation in measurement of homocysteine concentrations, we used differences in homocysteine concentrations between TT and CC genotypes rather than absolute homocysteine concentrations as a measure of geographical differences in dietary folate, as differences in homocysteine concentrations by MTHFR C677T genotype have been shown to be greater at lower levels of folate intake and are reduced after folate supplementation.14 We examined whether these differences were associated with the size of effect of the MTHFR genotype on coronary heart disease risk. Of the 20 studies that gave mean homocysteine concentrations and standard deviations by genotype, the differences ranged from -0.8 to 11 μmol/l (table 2). A random effects meta-analysis of mean difference in homocysteine concentrations between CC and TT genotypes found an overall difference of 2.24 μmol/l (95% confidence interval 1.55 to 2.94). In a meta-regression analysis we found evidence to suggest that differences in serum homocysteine concentrations by genotype were associated with the effect of genotype on coronary artery disease risk ( = 0.103, P = 0.02), although this does not take into account the uncertainty in homocysteine differences by genotype. This equates to an increase in the odds ratio of exponential 0.103 (0.019 to 0.186) or 1.11 (1.01 to 1.20) per 1 μmol/l increase in the difference in homocysteine concentrations between CC and TT genotypes.
Table 2 Studies reporting serum homocysteine concentrations (μmol/l) according to MTHFR genotype: homozygotes for the mutant allele (TT), heterozygotes (CT), and wild type homozygotes (CC)
We calculated the predicted odd ratios for coronary heart disease risk for given changes in homocysteine concentrations by region (table 1) and compared them with the Wald et al5 meta-analysis (table 3). Findings were broadly similar for increased odds of coronary heart disease associated with the CC genotype and the effect of a 5 μmol/l increase or a 3 μmol/l decrease in homocysteine concentration between our meta-analysis and Wald's.
Table 3 Summary results from three meta-analyses of MTHFR C677T and coronary heart disease
Discussion
to included studies are on bmj.com
We thank Borge Nordestgaard, Ray Meleady, Mark Roest, Donato Gemmati, Pier Mannucio Mannucci, and Deborah Payne for sending data from their studies for this meta-analysis. We thank Margaret Burke, information scientist, Cochrane Heart Group, for assistance with our searches. We also thank Roger Harbord for his statistical advice.
Contributors: All authors contributed to the literature search, selection of studies, data extraction, statistical analysis, interpretation of results, and writing the paper. SJL coordinated the writing of the paper and is the guarantor.
Funding: All researchers hold permanent positions at the University of Bristol.
Competing interests: None declared.
Ethical approval: Not needed.
References
Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002;31: 59-70.
Brattstr?m L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72: 315-23.
Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72: 324-32.
Clarke R. An updated review of the published studies of homocysteine and cardiovascular disease. Int J Epidemiol 2002;31: 70-1.
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325: 1202-6.
Davey Smith G, Ebrahim S. `Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32: 1-22.
Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized controlled trials. BMJ 1998;316: 894-8.
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326: 1419-23.
Davey Smith G, Harbord R, Ebrahim S. Fibrinogen, C-reactive protein and coronary heart disease: does mendelian randomization suggest the associations are non-causal? QJM 2004;97: 163-6.
Colhoun HM, McKeigue PM, Davey Smith, G. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361: 865-72.
Klerk M, Verhoef P, Clarke R, Blom HJ, Schouten EG. MTHFR 677CT polymorphism and risk of coronary heart disease. JAMA 2002;288: 2023-31.
Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen city heart study. Blood 2004;104: 3046-51.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327: 557-60.
Ashfield-Watt PA, Pullin CH, Whiting JM, Clark ZE, Moat SJ, Newcombe RG, et al. Methylenetetrahydrofolate reductase 677CT genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am J Clin Nutr 2002;76: 180-6.
Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365: 224-232.
Shioji K, Kokubo Y, Goto Y, Nonogi H, Iwai N. An association analysis between genetic polymorphisms of matrix metalloproteinase-3 and methylenetetrahydrofolate reductase and myocardial infarction in Japanese. J Thromb Haemost 2004;2: 527-8.
Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002;347: 1916-23.
Abu-Amero KK, Wyngaard CA, Dzimiri N. Prevalence and role of methylenetetrahydrofolate reductase 677 CT and 1298 AC polymorphisms in coronary artery disease in Arabs. Arch Pathol Lab Med 2003;127: 1349-52.
Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke 2005;36: 1581-7.
Oi S. Current status of prenatal management of fetal spina bifida in the world: worldwide cooperative survey on the medico-ethical issue. Childs Nerv Syst 2003;19: 596-9.
Taguchi H, Kobayashi M, Yoshino N, Hosokawa K. Do Japanese take more folate from traditional Japanese dish than is conventionally estimated? Actual folate contents in hospital diets and marketed lunch boxes. Asian Pacific J Cancer Prev 2004;5: 374-8.
Dusitanond P, Eikelboom JW, Hankey GJ, Thom J, Gilmore G, Loh K, et al. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. Stroke 2005;36: 144-6.
Spoelstra-de MA, Brouwer CB, Terheggen F, Bollen JM, Stehouwer CD, Smulders YM. No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia. Neth J Med 2004;62: 246-53.
Toole J, Malinow MCL, Spence J, Pettigrew L, Howard V, Sides E, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004;291: 565-75.
Baker F, Picton D, Blackwood S, Hunt J, Erskine M, Dyas M, et al. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial. Circulation 2002;106(suppl II): 741S.
Davey Smith G, Ebrahim S. Folate supplementation and cardiovascular disease: a familiar story. Lancet 2005; in press.
Khoury MJ, Little J. Human genome epidemiologic reviews: the beginning of something HuGE. Am J Epidemiol 2000;151: 2-3.
Minelli C, Thompson JR, Tobin MD, Abrams KR. An integrated approach to the meta-analysis of genetic association studies using mendelian randomization. Am J Epidemiol 2004;160: 445-52.(Sarah J Lewis, lecturer in genetic epide)
Correspondence to: S J Lewis s.j.lewis@bristol.ac.uk
Objectives To investigate the association between the MTHFR 677CT polymorphism and coronary heart disease, assessing small study bias and heterogeneity between studies.
Data sources Medline and Embase citation searches between January 2001 and August 2004; no language restrictions.
Study selection Case-control and prospective studies of association between MTHFR 677CT variant and myocardial infarction, coronary artery occlusion, or both; 80 studies were included.
Data extraction Data on genotype frequency and mean homocysteine concentrations by genotype were extracted. Odds ratios were calculated for TT genotype versus CC genotype. Heterogeneity was explored, with stratification by geographical region of the study samples, and meta-regression by difference in mean serum homocysteine concentrations (CC minus TT genotypes) was carried out.
Results 26 000 cases and 31 183 controls were included. An overall random effects odds ratio of 1.14 (95% confidence intervals 1.05 to 1.24) was found for TT versus CC genotype. There was strong evidence of heterogeneity (P < 0.001, I2 = 38.4%), which largely disappeared after stratification by geographical region. Odds ratios in Europe, Australia, and North America attenuated towards the null, unlike those in the Middle East and Asia.
Conclusions No strong evidence exists to support an association of the MTHFR 677 CT polymorphism and coronary heart disease in Europe, North America, or Australia. Geographical variability may be due to higher folate intake in North America and Europe or to publication bias. The conclusion drawn from previous meta-analyses that folic acid, through lowering homocysteine, has a role in prevention of cardiovascular disease is in some doubt.
Observational studies have consistently shown that higher plasma homocysteine concentrations are associated with an greater risk of coronary heart disease.1 However homocysteinecoronary heart disease associations may be confounded (for example, by smoking and socioeconomic position) and existing atherosclerosis could itself increase homocysteine concentrations.2 3 This last explanation (reverse causality) is supported by evidence that the homocysteine-coronary heart disease associations derived from cohort studies are weaker than those from case-control studies, which are, inevitably, more prone to being biased by existing disease leading to higher homocysteine concentrations.4
Associations between the genetic variant MTHFR 677CT and coronary heart disease have been reported.5 The genetic variant is associated with elevated homocysteine concentrations but, following the principles of mendelian randomisation,6 is not subject to reverse causation or the confounding that exists in observational studies of coronary heart disease risk in relation to directly measured homocysteine concentrations. Indeed, inclusion of folate—which lowers homocysteine concentrations7—in the proposed Polypill (a combination of low dose aspirin, a statin, three blood pressure lowering drugs, and folic acid, intended for prevention of coronary heart disease) is supported by reference to two meta-analyses of such genetic studies, and the evidence of causation is said to be "compelling."8 However, the sample sizes needed for studies to accurately estimate the causal influence of intermediate phenotypes such as homocysteine concentration on disease outcomes by using common genetic variants are necessarily very large,9 and publication bias (selective publication of positive findings) is likely to be a major concern with genetic association studies.10
In their meta-analysis, Wald et al tested for small study bias, reporting an Egger test of P = 0.55.5 Another meta-analysis of the association between MTHFR 677CT and coronary heart disease showed potential publication bias, in which non-publication of small negative studies would lead to overestimation of the strength of association between the MTHFR 677CT variant and coronary heart disease.11 Since the publication of these two meta-analyses several new studies have appeared, including one larger than any previous study.12 Adding these and studies already published but presumably missed by the search strategy used by previous investigators more than doubles the number of cases available for analysis compared with the two previous comprehensive meta-analyses.5 11 We have therefore carried out an updated meta-analysis using a comprehensive literature search and fully investigated potential publication bias. This work is important, as it is essential to define carefully the evidence for inclusion of folic acid in the Polypill, which has been strongly promoted, has been patented, and is in the process of being manufactured.
Methods
We identified eligible studies by searching Medline and Embase for all publications between January 2001 and August 2004, updating the search used in earlier meta-analyses.5 We used the search terms "mthfr," "methylenetetrahydrofolate reductase," "5,10 methylenetetrahydrofolate reductase," "677C," and "C677T" in combination with "cardiovascular disease," "ischemic heart disease," "coronary," "heart disease," "myocardial infarction," and "angina." We did not exclude any studies on the basis of language. We used the outcome as defined by previous investigators of myocardial infarction or coronary artery occlusion (> 50% of the luminal diameter).
We based unadjusted odds ratios on published genotype frequencies or extracted them directly from publications where raw data were not available. We used random effects models.
Where possible, we assessed whether the frequencies of CC, CT, and TT genotypes among controls in individual studies were consistent with the expected distribution (that is, in Hardy-Weinberg equilibrium) by using the Pearson 2 test. In line with previous work, we compared the TT genotype with the CC genotype. In our meta-analysis of all studies, we stratified by the geographical region in which the studies were done—Asia, Australia, the Middle East, North America, and Europe—and gave odds ratios by region. We quantified the extent of heterogeneity by using I2, which represents the percentage of total variation across studies that is attributable to heterogeneity rather than chance.13 Where mean serum homocysteine concentrations were given by genotype, we extracted these for all samples or for controls only where values for all samples were not provided or could not be calculated. We estimated the difference in serum homocysteine concentrations between CC and TT genotypes by using a random effects meta-analysis. We used meta-regression analysis to assess whether differences in serum homocysteine concentration affected MTHFR-disease associations. We used Stata version 8 for all statistical analyses.
We calculated the predicted odds ratio for coronary heart disease risk for a 5 μmol/l increase and a 3 μmol/l decrease in homocysteine concentrations, for comparison with the Wald et al meta-analysis,5 by raising the odds ratio and confidence intervals to the power of 5/2.24 (the overall difference in mean homocysteine between CC and TT genotypes) and to the power of -3/2.24.
Results
In all, we included 81 data points from 80 studies in this meta-analysis (table 1; fig 1), with a total of 26 000 cases and 31 813 controls. We identified 24 studies that we believe fitted the earlier reviews' inclusion criteria,5 11 but which were not included in either of the original meta-analyses either because they were not identified by the original search strategies or because they have been published since this meta-analysis. We found an overall random effect odds ratio for coronary artery disease comparing TT with CC genotypes of 1.14 (95% confidence interval 1.05 to 1.24). Five studies showed evidence to suggest (P < 0.05) that genotypes were not in Hardy-Weinberg equilibrium in controls. However, exclusion of these studies made very little difference to the overall result (odds ratio 1.15, 1.06 to 1.26). We also found evidence that effect estimates were related to study size, suggesting that small study bias, such as publication bias, may have distorted the findings (Egger test P = 0.03).
Table 1 Summary findings by geographical region: odds ratios for coronary heart disease comparing TT with CC genotypes, and difference in geometric mean serum homocysteine concentrations
Fig 1 Results of search strategy
We found strong evidence of between study heterogeneity (P < 0.001, I2 = 38.4%). Stratified analysis by geographical region removed much of the heterogeneity within Europe, North America, Australia, and the Middle East; the random effect odds ratio were 1.08 (0.99 to 1.18; Pheterogeneity = 0.19, I2 = 16.1%) among the 42 European studies, 0.93 (0.80 to 1.10; Pheterogeneity = 0.64, I2 = 0%) among the 15 North American studies, 1.04 (0.73 to1.49; Pheterogeneity = 0.97, I2 = 0%) among the three Australian studies, and 2.61 (1.81 to 3.75; Pheterogeneity = 0.57, I2 = 0%) among the five Middle Eastern studies (fig 2). Evidence of heterogeneity remained between Asian studies, but this was only apparent between Japanese studies and others and within studies done in Japan. The random effects odds ratio for Japanese studies was 1.71 (1.23 to 2.37; Pheterogeneity = 0.01, I2 = 62.5%); studies done in China, Taiwan, and Korea produced homogeneous results, with an overall odds ratio of 0.81 (0.60 to 1.10; Pheterogeneity = 0.41, I2 = 3.0%).
Fig 2 Association between MTHFR C677T polymorphism and coronary heart disease (TT versus CC genotype). *Unpublished data taken from Klerk et al, 2002 meta-analysis
To minimise the effect of inter-laboratory variation in measurement of homocysteine concentrations, we used differences in homocysteine concentrations between TT and CC genotypes rather than absolute homocysteine concentrations as a measure of geographical differences in dietary folate, as differences in homocysteine concentrations by MTHFR C677T genotype have been shown to be greater at lower levels of folate intake and are reduced after folate supplementation.14 We examined whether these differences were associated with the size of effect of the MTHFR genotype on coronary heart disease risk. Of the 20 studies that gave mean homocysteine concentrations and standard deviations by genotype, the differences ranged from -0.8 to 11 μmol/l (table 2). A random effects meta-analysis of mean difference in homocysteine concentrations between CC and TT genotypes found an overall difference of 2.24 μmol/l (95% confidence interval 1.55 to 2.94). In a meta-regression analysis we found evidence to suggest that differences in serum homocysteine concentrations by genotype were associated with the effect of genotype on coronary artery disease risk ( = 0.103, P = 0.02), although this does not take into account the uncertainty in homocysteine differences by genotype. This equates to an increase in the odds ratio of exponential 0.103 (0.019 to 0.186) or 1.11 (1.01 to 1.20) per 1 μmol/l increase in the difference in homocysteine concentrations between CC and TT genotypes.
Table 2 Studies reporting serum homocysteine concentrations (μmol/l) according to MTHFR genotype: homozygotes for the mutant allele (TT), heterozygotes (CT), and wild type homozygotes (CC)
We calculated the predicted odd ratios for coronary heart disease risk for given changes in homocysteine concentrations by region (table 1) and compared them with the Wald et al5 meta-analysis (table 3). Findings were broadly similar for increased odds of coronary heart disease associated with the CC genotype and the effect of a 5 μmol/l increase or a 3 μmol/l decrease in homocysteine concentration between our meta-analysis and Wald's.
Table 3 Summary results from three meta-analyses of MTHFR C677T and coronary heart disease
Discussion
to included studies are on bmj.com
We thank Borge Nordestgaard, Ray Meleady, Mark Roest, Donato Gemmati, Pier Mannucio Mannucci, and Deborah Payne for sending data from their studies for this meta-analysis. We thank Margaret Burke, information scientist, Cochrane Heart Group, for assistance with our searches. We also thank Roger Harbord for his statistical advice.
Contributors: All authors contributed to the literature search, selection of studies, data extraction, statistical analysis, interpretation of results, and writing the paper. SJL coordinated the writing of the paper and is the guarantor.
Funding: All researchers hold permanent positions at the University of Bristol.
Competing interests: None declared.
Ethical approval: Not needed.
References
Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002;31: 59-70.
Brattstr?m L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72: 315-23.
Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72: 324-32.
Clarke R. An updated review of the published studies of homocysteine and cardiovascular disease. Int J Epidemiol 2002;31: 70-1.
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325: 1202-6.
Davey Smith G, Ebrahim S. `Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32: 1-22.
Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized controlled trials. BMJ 1998;316: 894-8.
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326: 1419-23.
Davey Smith G, Harbord R, Ebrahim S. Fibrinogen, C-reactive protein and coronary heart disease: does mendelian randomization suggest the associations are non-causal? QJM 2004;97: 163-6.
Colhoun HM, McKeigue PM, Davey Smith, G. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361: 865-72.
Klerk M, Verhoef P, Clarke R, Blom HJ, Schouten EG. MTHFR 677CT polymorphism and risk of coronary heart disease. JAMA 2002;288: 2023-31.
Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen city heart study. Blood 2004;104: 3046-51.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327: 557-60.
Ashfield-Watt PA, Pullin CH, Whiting JM, Clark ZE, Moat SJ, Newcombe RG, et al. Methylenetetrahydrofolate reductase 677CT genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am J Clin Nutr 2002;76: 180-6.
Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365: 224-232.
Shioji K, Kokubo Y, Goto Y, Nonogi H, Iwai N. An association analysis between genetic polymorphisms of matrix metalloproteinase-3 and methylenetetrahydrofolate reductase and myocardial infarction in Japanese. J Thromb Haemost 2004;2: 527-8.
Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002;347: 1916-23.
Abu-Amero KK, Wyngaard CA, Dzimiri N. Prevalence and role of methylenetetrahydrofolate reductase 677 CT and 1298 AC polymorphisms in coronary artery disease in Arabs. Arch Pathol Lab Med 2003;127: 1349-52.
Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke 2005;36: 1581-7.
Oi S. Current status of prenatal management of fetal spina bifida in the world: worldwide cooperative survey on the medico-ethical issue. Childs Nerv Syst 2003;19: 596-9.
Taguchi H, Kobayashi M, Yoshino N, Hosokawa K. Do Japanese take more folate from traditional Japanese dish than is conventionally estimated? Actual folate contents in hospital diets and marketed lunch boxes. Asian Pacific J Cancer Prev 2004;5: 374-8.
Dusitanond P, Eikelboom JW, Hankey GJ, Thom J, Gilmore G, Loh K, et al. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. Stroke 2005;36: 144-6.
Spoelstra-de MA, Brouwer CB, Terheggen F, Bollen JM, Stehouwer CD, Smulders YM. No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia. Neth J Med 2004;62: 246-53.
Toole J, Malinow MCL, Spence J, Pettigrew L, Howard V, Sides E, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004;291: 565-75.
Baker F, Picton D, Blackwood S, Hunt J, Erskine M, Dyas M, et al. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial. Circulation 2002;106(suppl II): 741S.
Davey Smith G, Ebrahim S. Folate supplementation and cardiovascular disease: a familiar story. Lancet 2005; in press.
Khoury MJ, Little J. Human genome epidemiologic reviews: the beginning of something HuGE. Am J Epidemiol 2000;151: 2-3.
Minelli C, Thompson JR, Tobin MD, Abrams KR. An integrated approach to the meta-analysis of genetic association studies using mendelian randomization. Am J Epidemiol 2004;160: 445-52.(Sarah J Lewis, lecturer in genetic epide)